Literature DB >> 14981241

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.

Natàlia Reixach1, Songpon Deechongkit, Xin Jiang, Jeffery W Kelly, Joel N Buxbaum.   

Abstract

The transthyretin (TTR) amyloidoses are human diseases in which the misfolded TTR protein aggregates in tissues with subsequent visceral, peripheral, and autonomic nerve dysfunction. Recent reports have stressed the importance of oligomeric intermediates as major cytotoxic species in various forms of amyloidogenesis. We have examined the cytotoxic effects of several quaternary structural states of wild-type and variant TTR proteins on cells of neural lineage. TTR amyloid fibrils and soluble aggregates >100 kDa were not toxic. Incubation of TTR under the conditions of the cell assay and analysis by size-exclusion chromatography and SDS/PAGE reveal that monomeric TTR or relatively small, rapidly formed aggregates of a maximum size of six subunits were the major cytotoxic species. Small molecules that stabilize the native tetrameric state were shown to prevent toxicity. The studies are consistent with a model in which the misfolded TTR monomer rapidly aggregates to form transient low molecular mass assemblies (<100 kDa) that are highly cytotoxic in tissue culture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981241      PMCID: PMC365703          DOI: 10.1073/pnas.0400062101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  The genetics of the amyloidoses.

Authors:  J N Buxbaum; C E Tagoe
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 3.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

4.  Rational design of potent human transthyretin amyloid disease inhibitors.

Authors:  T Klabunde; H M Petrassi; V B Oza; P Raman; J W Kelly; J C Sacchettini
Journal:  Nat Struct Biol       Date:  2000-04

Review 5.  Therapeutic strategies for human amyloid diseases.

Authors:  James C Sacchettini; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

6.  Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.

Authors:  Bruce M Taylor; Ronald W Sarver; Gregory Fici; Roger A Poorman; Barry S Lutzke; Antonio Molinari; Thomas Kawabe; Karl Kappenman; Allen E Buhl; Dennis E Epps
Journal:  J Protein Chem       Date:  2003-01

7.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?

Authors:  Per Hammarström; Yoshiki Sekijima; Joleen T White; R Luke Wiseman; Amareth Lim; Catherine E Costello; Klaus Altland; Ferenc Garzuly; Herbert Budka; Jeffery W Kelly
Journal:  Biochemistry       Date:  2003-06-10       Impact factor: 3.162

8.  Only amyloidogenic intermediates of transthyretin induce apoptosis.

Authors:  Karin Andersson; Anders Olofsson; Ellen Holm Nielsen; Sven-Erik Svehag; Erik Lundgren
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

Review 9.  Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?

Authors:  Joel N Buxbaum
Journal:  Trends Biochem Sci       Date:  2003-11       Impact factor: 13.807

10.  Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Authors:  Per Hammarström; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Science       Date:  2003-01-31       Impact factor: 47.728

View more
  125 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  A possible therapeutic target for Lou Gehrig's disease.

Authors:  Soumya S Ray; Peter T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

3.  The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis.

Authors:  Sagar D Khare; Michael Caplow; Nikolay V Dokholyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-08       Impact factor: 11.205

4.  Fibril fragmentation in amyloid assembly and cytotoxicity: when size matters.

Authors:  Wei-Feng Xue; Andrew L Hellewell; Eric W Hewitt; Sheena E Radford
Journal:  Prion       Date:  2010-01-29       Impact factor: 3.931

5.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

6.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

7.  Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers.

Authors:  Volker Luibl; Jose M Isas; Rakez Kayed; Charles G Glabe; Ralf Langen; Jeannie Chen
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

8.  Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.

Authors:  Gal Bitan
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

9.  Monitoring Conformational Landscape of Ovine Prion Protein Monomer Using Ion Mobility Coupled to Mass Spectrometry.

Authors:  Guillaume Van der Rest; Human Rezaei; Frédéric Halgand
Journal:  J Am Soc Mass Spectrom       Date:  2016-10-18       Impact factor: 3.109

10.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.